GC Staff Report

New research suggests medications such as Ozempic and Mounjaro could offer benefits beyond weight loss and diabetes management, including the possibility of slowing biological aging.

Medications that have already transformed the treatment of diabetes and obesity may have another surprising benefit: helping the body age more slowly.

Preliminary research presented by pharmaceutical giants Novo Nordisk and Eli Lilly suggests that patients taking popular GLP-1 medications, including Ozempic, Wegovy, Mounjaro and Zepbound, may experience biological changes associated with being several years younger than their actual age.

The findings, presented at the 13th annual Aging Research & Drug Discovery (ARDD) conference, have generated interest among researchers exploring ways to improve health and potentially extend the number of years people live without serious illness.

Unlike chronological age, which measures how many years a person has lived, biological age reflects how well the body’s cells, tissues and organs are functioning. Scientists use specialized tests known as aging clocks to estimate biological age by examining changes in proteins, DNA and other indicators associated with aging.

Researchers at Novo Nordisk analyzed previous clinical trial data involving semaglutide, the active ingredient in Ozempic and Wegovy. Their analysis found that patients taking the medication appeared approximately two to three years biologically younger than participants receiving a placebo, depending on the aging clock used.

One measurement, which focused on proteins associated with cardiovascular health, suggested a difference of approximately four years.

Eli Lilly conducted a similar analysis involving tirzepatide, the active ingredient in Mounjaro and Zepbound. Unlike semaglutide, tirzepatide targets two hormones involved in regulating blood sugar and appetite: GLP-1 and GIP.

Using tests that examine chemical modifications to DNA, researchers found that patients taking tirzepatide also showed signs of reduced biological aging compared with those receiving a placebo.

The results raise intriguing possibilities, particularly for older adults and individuals managing chronic conditions such as diabetes, obesity and cardiovascular disease.

However, scientists caution that the findings are preliminary and should not be interpreted as proof that these medications actually reverse aging or extend human life.

Although the analyses drew on clinical trial data, the aging measurements themselves were exploratory. Different biological aging clocks produced different results, and researchers have not yet established whether improvements in those measurements translate into longer lives or fewer age-related diseases.

Another important question is whether the apparent anti-aging effects result directly from the medications or indirectly from improvements in weight, blood sugar levels, inflammation and cardiovascular health.

GLP-1 medications have already demonstrated significant benefits for certain patients beyond weight management, including reducing the risk of some cardiovascular complications. Researchers are continuing to investigate their potential effects on other age-related conditions.

Still, these medications are not without risks. Common side effects include nausea, vomiting and other digestive problems, while more serious complications can occur in some patients.

For now, experts emphasize that Ozempic, Mounjaro and similar drugs should be used for established medical indications under a healthcare professional’s supervision, not simply as treatments to prevent aging.

While the prospect of slowing the biological clock is exciting, additional independent research and long-term studies will be necessary to determine whether these early findings represent a genuine breakthrough in healthy aging.

The bottom line: These widely used medications may eventually offer benefits that extend beyond controlling diabetes and reducing weight. But whether they can actually help people live longer, healthier lives remains an important question that science has yet to answer.